|
Indications and Dosage
Subcutaneous
Prevention of recurrent attacks of hereditary angioedema Adult: Initially, 300 mg every 2 weeks. In patients who are well-controlled (e.g. attack free) for >6 months: 300 mg every 4 weeks. Dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).
Child: ≥12 years Same as adult dose. |
|
Contraindications
Hypersensitivity.
|
|
Special Precautions
Not indicated for acute hereditary angioedema attacks. Children. Pregnancy and lactation.
|
|
Adverse Reactions
Significant: Hypersensitivity reactions (e.g. pruritus, discomfort, tingling of tongue), antibody development.
Gastrointestinal disorders: Diarrhoea. General disorders and administration site conditions: Inj site reactions (e.g. pain, discomfort, erythema, bruising, haematoma, haemorrhage, swelling, pruritus, warmth, paraesthesia, induration, rash). Investigations: Increased ALT, AST. Musculoskeletal and connective tissue disorders: Myalgia. Nervous system disorders: Dizziness, headache. Respiratory, thoracic and mediastinal disorders: Upper respiratory tract infection. Skin and subcutaneous tissue disorders: Maculo-papular rash. |
|
Monitoring Parameters
Obtain LFTs. Monitor for signs and symptoms of hypersensitivity reaction.
|
|
Lab Interference
May increase aPTT as a result of an interaction with the aPTT assay.
|
|
Action
Description:
Mechanism of Action: Lanadelumab is a human monoclonal antibody (IgG1/kappa-light chain) that binds to plasma kallikrein and inhibits its proteolytic activity. This results in controlling excess production of bradykinin in patients with hereditary angioedema. Pharmacokinetics: Absorption: Time to peak plasma concentration: 4.11-5.17 days. Distribution: Volume of distribution: 14.1-16.6 L. Excretion: Elimination half-life: 14.2-15 days. |
|
Storage
Store between 2-8°C. Do not freeze. Do not shake. Protect from light. Storage recommendations may vary among individual products and between countries (refer to specific product guidelines).
|
|
MIMS Class
|
|
ATC Classification
B06AC05 - lanadelumab ; Belong to the class of drugs used in the treatment of hereditary angioedema.
|
|
References
Anon. Lanadelumab. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 15/12/2021. Buckingham R (ed). Lanadelumab. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 15/12/2021. Joint Formulary Committee. Lanadelumab. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 15/12/2021. Takhzyro (Takeda Pharmaceuticals America, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 15/12/2021. Takhzyro 300 mg Solution for Injection (Shire Pharmaceuticals Ireland Limited). MHRA. https://products.mhra.gov.uk. Accessed 15/12/2021. Takhzyro 300 mg Solution for Injection in Pre-filled Syringe (Shire Pharmaceuticals Ireland Limited). MHRA. https://products.mhra.gov.uk. Accessed 15/12/2021. Takhzyro Solution for Injection in Pre-filled Syringe 300 mg/2 mL (Takeda Pharmaceuticals [Hong Kong] Ltd). MIMS Hong Kong. http://www.mims.com/hongkong. Accessed 15/12/2021.
|
Sign Out
